Published December 2018 | Version v1
Journal article

The impact of in-hospital P2Y12 inhibitor switch in patients with acute coronary syndrome

  • 1. Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, United States of America (United States)
  • 2. Cardiovascular Branch, Division of Intramural Research, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, United States of America (United States)

Description

Dual antiplatelet therapy (DAPT) varies after placement of drug-eluting stents (DES) in patients presenting with acute coronary syndromes (ACS). Our aim was to study patient characteristics and predictors of switching, in-hospital or at discharge, from clopidogrel (CLO) to ticagrelor (TIC) or vice versa.

Additional details

Identifiers

DOI
10.1016/j.carrev.2018.09.007;
PII
S1553838918304081;

Publishing Information

Journal Title
Cardiovascular Revascularization Medicine (Print)
Journal Volume
19
Journal Issue
8
Journal Page Range
p. 912-916
ISSN
1553-8389

INIS

Country of Publication
Netherlands
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
55055147
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
CARDIOVASCULAR DISEASES; CORONARIES; DRUGS; HOSPITALS; PATIENTS; THERAPY
Descriptors DEC
ARTERIES; BLOOD VESSELS; BODY; BUILDINGS; CARDIOVASCULAR SYSTEM; DISEASES; MEDICAL ESTABLISHMENTS; MEDICINE; ORGANS

Optional Information

Copyright
Copyright (c) 2018 Elsevier Inc. All rights reserved.